Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.65 |
| ▸ | CTSG | P08311 | 1/20 | 0.64 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429826 | 1.00 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL7363457 | 1.00 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL7363455 | 1.00 | ELANE (0.65) | ELANECTSGCMA1 | |
| SCHEMBL18880036 | 0.90 | ELANE (0.68) | ELANECTSGCMA1 | |
| SCHEMBL7310675 | 0.90 | ELANE (0.80) | ELANECTSGCMA1 | |
| SCHEMBL17378380 | 0.90 | ELANE (0.68) | ELANECTSGCMA1 | |
| SCHEMBL13924699 | 0.89 | ELANE (0.56) | ELANECTSG | |
| SCHEMBL18880040 | 0.88 | ELANE (0.66) | ELANECTSGCMA1 | |
| SCHEMBL22686717 | 0.88 | ELANE (0.69) | ELANECTSGCMA1 | |
| SCHEMBL20943172 | 0.88 | ELANE (0.69) | ELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919493-B1 | USE OF SPECIFIC TRIFLUOROMETHYL KETONES FOR PREVENTING AND TREATING PANCREATITIS | LERCH MARKUS M (DE) | 2014-07-30 | — | — | EP | disclosed |
| US-20090042969-A1 | Use of Specific Trifluoromethyl Ketones for Preventing and Treating Pancreatitis | ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042969-A1 | Use of Specific Trifluoromethyl Ketones for Preventing and Treating Pancreatitis | ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD (DE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042969-A1 | Use of Specific Trifluoromethyl Ketones for Preventing and Treating Pancreatitis | PNLIP, AMY2A, FABP2 | ELANE 19/4885CTSG 164/4885CMA1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.